

Harald Murck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9492345/publications.pdf>

Version: 2024-02-01

87
papers

3,447
citations

117625

34
h-index

149698

56
g-index

89
all docs

89
docs citations

89
times ranked

3404
citing authors

#	ARTICLE	IF	CITATIONS
1	Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 631-642.	2.6	2
2	Ventricular volume, white matter alterations and outcome of major depression and their relationship to endocrine parameters – A pilot study. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 104-118.	2.6	9
3	Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety. <i>Journal of Psychiatric Research</i> , 2021, 137, 376-382.	3.1	13
4	Early onset of depression and treatment outcome in patients with major depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 139, 150-158.	3.1	22
5	Food Enrichment with <i>Glycyrrhiza glabra</i> Extract Suppresses ACE2 mRNA and Protein Expression in Rats – Possible Implications for COVID-19. <i>Nutrients</i> , 2021, 13, 2321.	4.1	16
6	The neurobiology of childhood trauma – aldosterone and blood pressure changes in a community sample. <i>World Journal of Biological Psychiatry</i> , 2021, , 1-9.	2.6	4
7	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. <i>Journal of Psychiatric Research</i> , 2020, 130, 82-88.	3.1	20
8	Adjunct Therapy With <i>Glycyrrhiza Glabra</i> Rapidly Improves Outcome in Depression – A Pilot Study to Support 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Inhibition as a New Target. <i>Frontiers in Psychiatry</i> , 2020, 11, 605949.	2.6	7
9	Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?. <i>Frontiers in Immunology</i> , 2020, 11, 1239.	4.8	104
10	F71. Neuroendocrine Determinants of Structural Brain Parameters and Treatment Outcome in Major Depression. <i>Biological Psychiatry</i> , 2019, 85, S240.	1.3	0
11	T81. Gait Disturbances in Major Depression: Is There a Relationship to Normal Pressure Hydrocephalus?. <i>Biological Psychiatry</i> , 2019, 85, S160.	1.3	0
12	Markers of mineralocorticoid receptor function. <i>International Clinical Psychopharmacology</i> , 2019, 34, 18-26.	1.7	15
13	Mineralocorticoid receptor-related markers and outcome of major depression. <i>International Clinical Psychopharmacology</i> , 2018, 33, 224-228.	1.7	9
14	Sleep-endocrine effects of growth hormone-releasing hormone (GHRH) in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2018, 101, 1-4.	3.1	3
15	Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 155-161.	1.4	26
16	[P3 – 027]: RESULTS OF A PHASE 2 STUDY OF NELOTANSERIN, A NOVEL 5HT2A RECEPTOR INVERSE AGONIST, IN LEWY BODY DEMENTIA SUBJECTS EXPERIENCING VISUAL HALLUCINATIONS. <i>Alzheimer's and Dementia</i> , 2017, 13, P940.	0.8	0
17	[P4 – 588]: EVALUATION OF THE NEUROPROTECTIVE EFFECT OF INTEPIRDINE IN AN IN VITRO OXYGEN/GLUCOSE DEPRIVATION – INDUCED CYTOTOXICITY MODEL. <i>Alzheimer's and Dementia</i> , 2017, 13, P1579 ^{0.8}		0
18	Aldosterone Action on Brain and Behavior. , 2017, , 159-179.		4

#	ARTICLE	IF	CITATIONS
19	Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression. <i>Journal of Psychiatric Research</i> , 2015, 66-67, 24-37.	3.1	42
20	Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2015, 12, 26S-40S.	0.1	15
21	Genetic, Molecular and Clinical Determinants for the Involvement of Aldosterone and Its Receptors in Major Depression. <i>Nephron Physiology</i> , 2014, 128, 17-25.	1.2	27
22	New paradigms for treatment-resistant depression. <i>Annals of the New York Academy of Sciences</i> , 2013, 1292, 21-31.	3.8	89
23	Ketamine, magnesium and major depression – From pharmacology to pathophysiology and back. <i>Journal of Psychiatric Research</i> , 2013, 47, 955-965.	3.1	56
24	Renin-Angiotensin-Aldosterone System: The Forgotten Stress Hormone System: Relationship to Depression and Sleep. <i>Pharmacopsychiatry</i> , 2012, 45, 83-95.	3.3	60
25	Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 247-265.	2.1	62
26	Sub-chronic dietary tryptophan depletion – An animal model of depression with improved face and good construct validity. <i>Journal of Psychiatric Research</i> , 2012, 46, 239-247.	3.1	30
27	<i>Hypericum perforatum</i> differentially affects corticosteroid receptor-mRNA expression in human monocytic U-937 cells. <i>Journal of Psychiatric Research</i> , 2011, 45, 1170-1177.	3.1	1
28	Changes in the sleep electroencephalogram (EEG) during male to female transgender therapy. <i>Psychoneuroendocrinology</i> , 2011, 36, 1005-1009.	2.7	20
29	St. John's wort extract LI160 for the treatment of depression with atypical features – A double-blind, randomized, and placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2010, 44, 760-767.	3.1	31
30	Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 57-61.	4.8	55
31	The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression – An MR spectroscopy study. <i>Journal of Psychiatric Research</i> , 2009, 43, 175-180.	3.1	34
32	Pituitary adenylate cyclase-activating peptide affects homeostatic sleep regulation in healthy young men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E853-E857.	3.5	18
33	Ethyl-EPA in Huntington disease – Potentially relevant mechanism of action. <i>Brain Research Bulletin</i> , 2007, 72, 159-164.	3.0	30
34	<i>Hypericum</i> Extract Reverses S-Ketamine-Induced Changes in Auditory Evoked Potentials in Humans – Possible Implications for the Treatment of Schizophrenia. <i>Biological Psychiatry</i> , 2006, 59, 440-445.	1.3	15
35	The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. <i>Schizophrenia Research</i> , 2006, 84, 112-120.	2.0	83
36	Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. <i>Psychoneuroendocrinology</i> , 2006, 31, 100-107.	2.7	56

#	ARTICLE	IF	CITATIONS
37	Effect of Sub-Chronic Treatment with Jarsin [®] (Extract of St John [™] s Wort, Hypericum perforatum) at Two Dose Levels on Evening Salivary Melatonin and Cortisol Concentrations in Healthy Male Volunteers. <i>Pharmacopsychiatry</i> , 2006, 39, 13-15.	3.3	14
38	Renin-Angiotensin-Aldosterone System, HPA-Axis and Sleep-EEG Changes in Unmedicated Patients with Depression after Total Sleep Deprivation. <i>Pharmacopsychiatry</i> , 2006, 39, 23-29.	3.3	29
39	Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 215-221.	2.1	14
40	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	1.4	116
41	Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. <i>Psychoneuroendocrinology</i> , 2005, 30, 29-37.	2.7	30
42	Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers. <i>Psychopharmacology</i> , 2005, 180, 327-332.	3.1	6
43	Alpha-Helical CRH Exerts CRH Agonistic Effects on Sleep-Endocrine Activity in Humans. <i>Neuropsychobiology</i> , 2005, 52, 62-67.	1.9	9
44	Reboxetine Induces Similar Sleep-EEG Changes Like SSRI [™] s in Patients with Depression. <i>Pharmacopsychiatry</i> , 2004, 37, 193-195.	3.3	24
45	Effects of Hypericum Extract (LI160) on the Change of Auditory Evoked Potentials by Cortisol Administration. <i>Neuropsychobiology</i> , 2004, 50, 128-133.	1.9	4
46	The Somatostatin Analogue Octreotide Impairs Sleep and Decreases EEG Sigma Power in Young Male Subjects. <i>Neuropsychopharmacology</i> , 2004, 29, 146-151.	5.4	41
47	Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. <i>Psychoneuroendocrinology</i> , 2004, 29, 1205-1211.	2.7	61
48	Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. <i>Psychoneuroendocrinology</i> , 2004, 29, 851-860.	2.7	33
49	Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. <i>Journal of Psychiatric Research</i> , 2004, 38, 129-136.	3.1	129
50	Sub-chronic treatment with an extract of Hypericum perforatum (St John [™] s wort) significantly reduces cortisol and corticosterone in the rat brain. <i>European Neuropsychopharmacology</i> , 2004, 14, 7-10.	0.7	14
51	Magnesium-deficient diet alters depression- and anxiety-related behavior in mice [™] influence of desipramine and Hypericum perforatum extract. <i>Neuropharmacology</i> , 2004, 47, 1189-1197.	4.1	139
52	Treatment of Somatoform Disorders With St. John [™] s Wort: A Randomized, Double-Blind and Placebo-Controlled Trial. <i>Psychosomatic Medicine</i> , 2004, 66, 538-547.	2.0	71
53	Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 341-349.	2.1	47
54	On the role of menopause for sleep-endocrine alterations associated with major depression. <i>Psychoneuroendocrinology</i> , 2003, 28, 401-418.	2.7	43

#	ARTICLE	IF	CITATIONS
55	Society News: Eur. J. Lipid Sci. Technol. 7/2003. European Journal of Lipid Science and Technology, 2003, 105, 386-387.	1.5	0
56	Atypical depression spectrum disorder – neurobiology and treatment. Acta Neuropsychiatrica, 2003, 15, 227-241.	2.1	34
57	The Renin-Angiotensin-Aldosterone system in patients with depression compared to controls – a sleep endocrine study. BMC Psychiatry, 2003, 3, 15.	2.6	88
58	Dr. David F. Horrobin. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 1-26.	2.2	1
59	State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine. Neuropsychopharmacology, 2003, 28, 348-358.	5.4	56
60	Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression. Journal of Clinical Psychopharmacology, 2003, 23, 155-168.	1.4	141
61	Increase in Amino Acids in the Pons after Sleep Deprivation: A Pilot Study Using Proton Magnetic Resonance Spectroscopy. Neuropsychobiology, 2002, 45, 120-123.	1.9	24
62	Magnesium and Affective Disorders. Nutritional Neuroscience, 2002, 5, 375-389.	3.1	130
63	Oral Mg ²⁺ Supplementation Reverses Age-Related Neuroendocrine and Sleep EEG Changes in Humans. Pharmacopsychiatry, 2002, 35, 135-143.	3.3	72
64	Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. Journal of Psychiatric Research, 2002, 36, 189-196.	3.1	31
65	St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology, 2002, 164, 294-300.	3.1	86
66	Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT _{1A} agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology, 2001, 155, 187-192.	3.1	45
67	Temporal EEG dynamics of non-REM sleep episodes in humans. Brain Research, 2000, 861, 233-240.	2.2	12
68	Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology, 2000, 39, 1474-1481.	4.1	118
69	On the Gender Differences in Sleep-Endocrine Regulation in Young Normal Humans. Neuroendocrinology, 1999, 70, 280-287.	2.5	61
70	Hyporesponsiveness of the Pituitary to CRH during Slow Wave Sleep Is Not Mimicked by Systemic GHRH. Neuroendocrinology, 1999, 69, 88-96.	2.5	22
71	Effects of Growth Hormone-Releasing Peptide on the Nocturnal Secretion of GH, ACTH and Cortisol and on the Sleep EEG in Man: Role of Routes of Administration. Journal of Neuroendocrinology, 1999, 11, 473-478.	2.6	24
72	Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls. Psychopharmacology, 1999, 141, 107-110.	3.1	10

#	ARTICLE	IF	CITATIONS
73	Galanin has REM-sleep deprivation-like effects on the sleep eeg in healthy young men. Journal of Psychiatric Research, 1999, 33, 225-232.	3.1	35
74	Aging does not affect the sleep endocrine response to total sleep deprivation in humans. Neurobiology of Aging, 1999, 20, 665-668.	3.1	23
75	Nocturnal Hormone Secretion and the Sleep EEG in Patients Several Months After Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 354-360.	1.8	43
76	Elevated nocturnal profiles of serum leptin in patients with depression. Journal of Psychiatric Research, 1998, 32, 403-410.	3.1	125
77	Mg 2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men - possible therapeutic implications. Psychopharmacology, 1998, 137, 247-252.	3.1	33
78	Effects of Hormones on Sleep. Hormone Research in Paediatrics, 1998, 49, 125-130.	1.8	57
79	Enhanced Slow Wave Sleep in Patients with Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2706-2710.	3.6	49
80	Resting Membrane Properties of Locust Muscle and Their Modulation I. Actions of the Neuropeptides YGGFMRamide and Proctolin. Journal of Neurophysiology, 1998, 80, 771-784.	1.8	17
81	Longtime Administration of Growth Hormone-Releasing Hormone (GHRH) does not Restore the Reduced Efficiency of GHRH on Sleep Endocrine Activity in 2 Old-Aged Subjects - a Preliminary Study. Pharmacopsychiatry, 1997, 30, 122-124.	3.3	14
82	Cortisol Enhances non-REM Sleep and Growth Hormone Secretion in Elderly Subjects. Neurobiology of Aging, 1997, 18, 423-429.	3.1	60
83	Somatostatin Impairs Sleep in Elderly Human Subjects. Neuropsychopharmacology, 1997, 16, 339-345.	5.4	63
84	Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology, 1997, 132, 82-88.	3.1	48
85	Growth Hormone-Releasing Peptide-6 Stimulates Sleep, Growth Hormone, ACTH and Cortisol Release in Normal Man. Neuroendocrinology, 1995, 61, 584-589.	2.5	115
86	REM sleep in patients with depression. , 0, , 383-394.		1
87	Magnesium and major depression. , 0, , 313-332.		6